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ARTICLE
Stromal and epithelial transcriptional map of
initiation progression and metastatic potential of
human prostate cancer
Svitlana Tyekucheva1,2, Michaela Bowden3, Clyde Bango4, Francesca Giunchi5, Ying Huang4,
Chensheng Zhou 3, Arrigo Bondi6, Rosina Lis3,7, Mieke Van Hemelrijck8, Ove Andrén9, Sven-Olof Andersson9,
R. William Watson10, Stephen Pennington10, Stephen P. Finn11, Neil E. Martin12, Meir J. Stampfer13,14,15,
Giovanni Parmigiani1,2, Kathryn L. Penney13,14, Michelangelo Fiorentino5, Lorelei A. Mucci13,14 &
Massimo Loda4,7,16
While progression from normal prostatic epithelium to invasive cancer is driven by
molecular alterations, tumor cells and cells in the cancer microenvironment are co-dependent
and co-evolve. Few human studies to date have focused on stroma. Here, we performed gene
expression proﬁling of laser capture microdissected normal non-neoplastic prostate epithelial
tissue and compared it to non-transformed and neoplastic low-grade and high-grade prostate
epithelial tissue from radical prostatectomies, each with its immediately surrounding stroma.
Whereas benign epithelium in prostates with and without tumor were similar in gene
expression space, stroma away from tumor was signiﬁcantly different from that in prostates
without cancer. A stromal gene signature reﬂecting bone remodeling and immune-related
pathways was upregulated in high compared to low-Gleason grade cases. In validation
data, the signature discriminated cases that developed metastasis from those that did not.
These data suggest that the microenvironment may inﬂuence prostate cancer initiation,
maintenance, and metastatic progression.
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The prostate consists of the glandular epithelium andsupporting stroma. This connective stroma is comprised ofﬁbroblasts, myoﬁbroblasts, smooth muscle cells, vascular
endothelial cells, nerve cells, and inﬂammatory cells. While
prostate cancer arises from the epithelial component of the
gland, the surrounding stroma is increasingly recognized as an
important contributor in the process of carcinogenesis1, 2 and a
driver of cancer progression. Experimental models
demonstrate that altered stromal cells can induce tumor
formation in non-cancerous prostate epithelial cells2 and in cell
lines derived from prostate cancer3. Benign prostate
epithelial cells are more proliferative and ultimately undergo
transformation when combined with prostate cancer-derived
ﬁbroblasts2, 4. It is also clear that the stroma can morphologically
and functionally change in the presence of cancer and other
insults. Compared to normal stroma, there is a switching of the
cellular phenotype5, remodeling of the extracellular matrix6
increases in expression of growth factors and proteases7
increased angiogenesis8, and change in inﬂammatory cells9.
The bidirectional signaling between epithelial cells and stromal
constituents during normal prostate homeostasis is disrupted
early in tumorigenesis (reviewed in ref. 10). The consequences
are diverse and range from deposition of extracellular matrix,
to recruitment of inﬂammatory cells, production of miRNA,
promotion of tissue regeneration and angiogenesis,
ultimately resulting in stimulation of growth and survival of
tumor cells11–13. When the stromal compartment becomes
reactive, normal ﬁbroblasts are replaced by cancer-associated
ﬁbroblasts (CAFs). The increase of CAFs, which begins around
in situ lesions, evolves during prostate tumorigenesis and is
inversely proportional to tumor differentiation14.
Signaling factors from the microenvironment inﬂuence
epithelial cells to acquire properties such as increased motility,
proliferation or migratory and invasive behavior. To this end,
TGFβ and Wnt signaling pathways have been shown to play
important regulatory roles in stromal-epithelial interactions in
both prostate development and tumorigenesis10, 15, 16. A variety
of additional growth factors produced by stromal cells
affect tumor cell survival17. In addition, soluble cytokine and
chemokines inﬂuence the interaction between the epithelial and
stromal compartments during prostate cancer progression. For
example, peri-prostatic adipose tissue can affect migration of
prostate cancer cells via secretion of CCL7 by adipocytes18.
Finally, androgen receptor, expressed by a subset of
myoﬁbroblasts in the prostate stroma, may regulate the
expression of growth factors secreted by these cells19. Thus,
tumor growth and biologic behavior is strongly regulated by
the extracellular milieu.
Most human studies have focused on the mutational
landscapes in tumors in an attempt to predict biologic and
clinical behavior of human prostate cancer20, 21. In addition,
epigenetic and transcriptional epithelial signatures are
associated with the degree of differentiation and are an important
adjunct in predicting aggressive and indolent behavior22–24.
While these contribute to additional independent prognostic
information, they could be further improved by knowledge of the
contribution of stromal elements. While it has been recently
shown that the stroma adjacent to prostate cancer epithelium
does not harbor clonal DNA alterations and appears to be
genetically stable25, biological behavior of the epithelial compo-
nent of the tumor, may be affected by variability of gene
expression in the stroma. In turn, epithelial alterations may
condition stromal behavior. For instance, hyperactivated focal
adhesion kinase (FAK) activity has been shown to be an impor-
tant regulator of the ﬁbrotic and immunosuppressive stromal
microenvironment in pancreatic cancer26. Additionally, stromal
gene expression signatures predict outcome in breast27–29 and
colorectal30 cancer patients.
Laser capture microdissection (LCM) has facilitated the
isolation and study of speciﬁc cellular populations within the
prostate tumor microenvironment. This labor-intensive
technology, however, limits large-scale studies. To date, differ-
ences between the tumor and its adjacent stroma in prostate
cancer31 between normal and reactive stroma32, and differences
between benign and tumor epithelium32–34 have been
addressed utilizing LCM, albeit on a small scale. Prior analyses
were centered predominantly on the epithelial compartment.
Limited studies of stromal gene expression using high-throughput
assays exist for prostate cancer aggressiveness. One such study
showed alterations in neurogenesis, axonogenesis, and DNA
damage/repair pathway to be associated with grade 3 reactive
stroma32.
Here, we hypothesize that progression of normal prostate
to prostatic intraepithelial neoplasia (PIN) to invasive cancer is
driven by molecular alterations in both epithelium and
stroma, and that changes in the microenvironment can
potentially contribute to tumor initiation, maintenance and
progression. We ﬁnd that gene expression of non-transformed
epithelial and stromal tissues differ in prostates with and without
tumor, and how the stromal genes are associated with prostate
cancer progression and aggressiveness.
Results
Experimental design. We performed gene expression proﬁling of
laser capture microdissected tissue specimens from 12 low-grade
(Gleason 3 + 3) and 13 high-grade (Gleason 8 and higher) radical
prostatectomy (RP) and 5 cystoprostatectomy cases. For each RP
case, we took 6 regions of interest: tumor (T), PIN (P) and benign
(B) epithelium each with its adjacent stroma (sT, sP, sB).
Table 1 Clinical characteristics of the LCM cohort
Total number of cases 30
Mean (s.d.) age at diagnosis 63.7 (7.7)
Clinical stage
T1 4
T1c 1
T2 12
T2a 2
T3 1
M1 1
NA 7
Pathological stage
pT1 2
pT2 4
pT2a 2
pT2b 1
pT2c 7
pT3a 4
pT3b 4
M1 1
NA 5
Gleason score
3 + 3 12
≥8 13
Tissue type
RP 25
Cystoprostatectomy 5
RP radical prostatectomy, s.d. standard deviation
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For cystoprostatectomy we studied benign epithelium and
adjacent stroma (H.B and H.sB). Cystoprostatectomies were
conﬁrmed not to harbor prostate cancer foci through review of
the entire submitted specimen. Clinicopathological features of the
cohort are described in Table 1.
Differences between compartments across progression.
As expected from our experimental design, the major share of
variability in gene expression was explained by
differences between epithelial and stromal tissue compartments
(Supplementary Fig. 1A). Many of the differentially expressed
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Fig. 1 Heatmaps of the GO biological processes enriched in a epithelial and b stromal compartments across healthy prostate tissues and stages of prostate
cancer progression. The cells in the heatmaps are colored according to the FDR of the process in the gene set analysis. Dark blue color corresponds to
signiﬁcance at 0.05 level and yellow to FDR> 0.2. Categories across compartments show conserved to unique processes from H to B to P to T. Most
relevant pathways are summarized in categories: Category 1 (top) epithelial: amino acid metabolism; Category 2 epithelial: secretory pathway; Category 3
epithelial: RNA synthesis; Category 4 epithelial: RNA, protein, and lipid synthesis; Category 5 epithelial: miscellaneous; Category 1 (top) stromal: muscle
development and localization; Category 2 stromal: immune regulation, angiogenesis and cell proliferation; Category 3 stromal: signal transduction, cell
migration and angiogenesis; Category 4 stromal: TGF beta, signal transduction and bone remodeling; Category 5 stromal: miscellaneous
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genes as well as pathways were shared across the H.B-H.sB, B-sB,
P-sP and T-sT comparisons (Supplementary Fig. 1B and Fig. 1).
The GO biological processes commonly upregulated in the
epithelium, and which were maintained through “progression”
to invasive tumors, included amino acid metabolism,
RNA processing, protein translation and post-translational
modiﬁcation (Fig. 1a).
Common processes upregulated in stroma were mostly
comprised of muscle development as well as changes in
cytoskeletal structure (Fig. 1b). Among processes upregulated in
all stromal components of the RP specimens, we ﬁnd increasing
occurrence of immune-related pathways, such as lymphocyte
differentiation and activation. Interestingly, the bone remodeling
pathway was upregulated more strongly in the stroma adjacent to
the tumors.
Differences within compartments across progression. As proof
of principle examples, TP63, a marker of normal basal cells of
the prostate gland was upregulated in benign microdissected
epithelial samples compared to invasive cancer, while
AMACR and ERG were all upregulated in the tumor
microdissected epithelial samples compared to benign epithelium
and, to a lesser extent, PIN (Supplementary Fig. 2).
Gene set analysis in tumor epithelium showed pathways
associated with nucleotide metabolism, translation, and RNA
processing (Fig. 2a). Translation, protein folding, as well as
negative regulation of apoptosis were upregulated in the tumor
adjacent stroma (Fig. 2b). Muscle development GO biological
process decreased in tumor-associated stroma, consistent with the
transformation of stromal composition from mainly muscle cells
to myoﬁbroblasts and ﬁbroblasts.
Differences between RP and cystoprostatectomy cases. We
compared the benign epithelial glands from the cystoprosta-
tectomy and RP (B-H.B) and found 15 differentially expressed
probesets (moderated t-tests, FDR< 0.05, FC≥1.5; Fig. 3a). In the
comparisons of the adjacent stroma from the cystoprostatectomy
and RP tissues (sB-HsB), a larger number of probesets (n= 130;
Fig. 3b, c) were statistically signiﬁcant. Forty-two of them were
probesets corresponding to small nucleolar mRNAs (almost all C/
D box), all overexpressed in normal stroma from RP specimens.
The GO biological processes associated with the sB-HsB differ-
entially expressed genes included N-linked glycosylation,
membrane and Golgi transport, and the unfolded protein
response (Fig. 3d).
Interestingly, the hierarchical clustering revealed greater
similarity in the expression of stromal genes between stroma
adjacent to benign epithelium in the prostates with no tumor
(cystoprostatectomies) and the benign stroma from prostates
with high-grade tumors. Similar effect is observed using
principal component analysis (PCA) projection of all genes
(Supplementary Fig. 3), even though the physical distance
between sB regions selected for analysis and the closest tumor
focus, on average was smaller for high-grade cases (t-test;
P= 0.04). This might suggest, that stroma surrounding Gleason
3 + 3 cases is inherently different. In the direct comparisons of the
sB from high-grade and low-grade cases no genes reached
statistical signiﬁcance.
Differences between high-grade and low-grade tumors.
Gleason grade is one of the strongest clinical predictors
of prostate cancer progression and outcomes. We
identiﬁed genes differentially expressed between high-grade
and low-grade epithelium (T.high-T.low) and in adjacent
stroma (sT.high-sT.low). A TGF-β-responsive marker and
functional regulator of prostate cancer metastasis to bone,
ALCAM (FDR= 0.005)35 was identiﬁed as the only signiﬁcantly
differentially expressed gene in the epithelium comparison.
Differences between gene expression in the sT.high-sT.low
comparison, however, were more striking with 27 probesets
corresponding to 24 unique gene symbols were differentially
expressed in stroma (Table 2). All genes were upregulated
in high-Gleason grade cases. The genes comprising this
stromal signature include a group of genes overexpressed
in osteoblasts and osteoblast-like cells, as well as some gene
overexpressed in macrophages, T and B cells, even though these
cells were scant (Supplementary Data 1 and Supplementary
Fig. 4). GO biological processes involved in immune response as
well as complement activation and skeletal system development
were signiﬁcantly enriched in our signature (Supplementary
Data 2). This signature features wound healing and metasta-
sis markers (SFRP2, SFRP4, THBS2), hematopoietic
bone marrow markers (SULF1, COL1A1), immune cell
markers (HLA-DRB1, FCGR2C), and complement cascade genes
(C1S, C1QA, C1QB, C1QC).
The single sample gene set enrichment (ssGSEA36) score
was used to summarize expression of these 27 probesets in the
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Fig. 2 GO biological processes differentially enriched between a Benign and tumor epithelium; b Benign and tumor adjacent stroma. Lengths of the bars are
equal to −log10(FDR) values from the gene set analysis. Negative values indicate enrichment in benign epithelium or stroma, respectively, positive values
indicate enrichment in the tumor or tumor adjacent stroma
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tumor-associated stroma by a single number in order to study
behavior of this group of genes as a whole. When comparing the
high and low-Gleason score cases, the difference in the score was
highly statistically signiﬁcant (Fig. 4a; t-test, P≤ 10−3). Interest-
ingly, while none of the individual genes from the signature
reached statistical signiﬁcance when stroma surrounding benign
glands in the prostates bearing high-Gleason and low-Gleason
cancers was compared (sB.high-sB.low), the difference in ssGSEA
scores for this comparison was marginally signiﬁcant (Fig. 4b; t-
test, P= 0.08).
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Fig. 3 Genes and pathways differentially expressed in benign tissue between cystoprostatectomy and RP specimens. a Heatmap of genes differentially
expressed in benign epithelium of prostate cancer patients and cystoprostatectomy patients without prostate cancer. Gleason grade corresponds to the
grade of the prostate tumor present in the block and NT (no tumor) denotes cystoprostatectomy cases. b Heatmap of genes and c heatmap of SNORDs
differentially expressed in stroma surrounding benign glands from prostate cancer patients and cystoprostatectomy patients without prostate cancer.
d –Log10 FDR-values from the pathways analysis of the genes differentially expressed in benign stroma using GO biological processes annotations
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Validation in external data. Next the stromal signature (Table 2)
was applied to the prostate data from The Cancer Genome
Atlas20. In a comprehensive re-review of these 333 tumor samples
by a group of GU pathologists a large variation in tumor purity
was reported. Specimens with low purity contain a lot of stroma,
which made them good candidates for preliminary validation of
this stromal signature associated with Gleason grade. Cases were
grouped into those with relatively high stromal content
(tumor cellularity ≤ 40%) and cases enriched for tumor epithe-
lium (tumor cellularity ≥ 80%). ssGSEA score of the stromal gene
signature was calculated. A signiﬁcant difference of the ssGSEA
signature score between 3 + 3 and 8 + Gleason in both
low tumor cellularity (Fig. 4c; t-test, P= 0.006) and high tumor
cellularity (Fig. 4d; t-test, P= 0.02) subsets was found, but the
difference was smaller and less signiﬁcant in high cellularity
samples, despite the larger sample size. This demonstrates
that while it is possible to observe signal from the stromal
genes in specimens with relatively low stromal content, it might
be signiﬁcantly diluted. Therefore, it is important to interpret
prostate expression data as a function of stromal content.
Similarly, the signature was applied to stromally enriched
samples (see Methods section) from the publicly available gene
expression data from the Mayo clinic cohort37 (GEO accession
number GSE46691). The signature was signiﬁcantly
different between high-Gleason grade and low-Gleason grade
samples (t-test, P< 2×10−10), and between cases that did or did
not develop metastasis (Fig. 4d). The AUC of the signature
score alone for predicting metastatic events using logistic
regression model was 0.67, and together with Gleason score
0.74. In this cohort, Gleason score alone predicted outcome with
AUC of 0.70.
Validation using immunohistochemistry. Protein expression
of selected genes in the signature was tested by immunohis-
tochemistry (IHC) to verify cell of origin. Only genes with
IHC-validated antibodies were tested. As examples, the
only signiﬁcant gene in the epithelial compartment, ALCAM
was overexpressed in the epithelial component of Gleason 8
tumors (Fig. 4f, g), and the stromal gene SULF1 was highly
expressed in stroma adjacent to high-grade, but not low-grade
tumor (Fig. 4h, i).
Discussion
The traditional consensus is that tumorigenesis is caused by
mutations exclusive to epithelial cells that promote increased
growth and invasive capacity, eventually resulting in metastasis.
For some time, compelling data primarily derived from
pre-clinical models have suggested that the microenvironment
within which the cancer cells reside plays a pivotal role in cancer
initiation and progression. Further, altered microenvironment
may even precede genetic alterations in epithelial cells. Our
results show that changes in the microenvironment are important
contributors to tumor initiation and may affect progression.
We observed that stromal, but not the epithelial gene
expression, obtained from benign areas (away from invasive
tumors) in RP specimen differs signiﬁcantly from that of
prostates without cancer. Pathways such as N-glycosylation and
the unfolded protein response (UPR) were upregulated in RP
benign stroma compared to cystoprostatectomy specimens. These
pathways are important in a variety of biological processes such
as nutrient sensing or control of lipogenesis and are commonly
altered in cancer. For instance, UPR can be an androgen
Table 2 Genes differentially expressed between stroma adjacent to high-Gleason grade and low-Gleason grade tumors in LCM
data and publicly available studies used for validation
Affy ID Gene symbol LCM TCGA GSE46691
Gleason Outcome
logFC P-value FDR P-value FDR P-value FDR P-value FDR
8132557 AEBP1 0.987 <10−4 0.011 0.004 0.015 0.009 0.019 0.024 0.041
8042439 ANTXR1 0.841 <10−4 0.042 0.015 0.032 0.002 0.005 0.003 0.013
8170648 BGN 1.059 <10−4 0.012 0.009 0.024 <10−4 <10−4 0.004 0.015
7898793 C1QA 0.747 <10−4 0.007 0.115 0.132 0.159 0.190 0.087 0.105
7898805 C1QB 0.786 <10−4 0.012 0.180 0.197 0.084 0.106 0.046 0.065
7898799 C1QC 1.014 <10−4 0.012 0.103 0.131 0.002 0.005 0.001 0.007
7960744 C1R 0.865 <10−4 0.042 0.076 0.117 0.061 0.081 0.067 0.084
7953603 C1S 1.005 <10−4 0.026 0.099 0.131 0.029 0.044 0.017 0.032
8001800 CDH11 0.711 <10−4 0.046 0.017 0.033 <10−4 0.002 0.002 0.010
8016646 COL1A1 1.149 <10−4 0.012 0.001 0.003 0.001 0.003 0.006 0.015
8046922 COL3A1 0.867 <10−4 0.043 0.004 0.015 0.001 0.003 0.012 0.024
7980908 FBLN5 0.849 <10−4 0.026 0.047 0.084 0.058 0.081 0.033 0.050
7906767 FCGR2B 0.747 <10−4 0.002 0.082 0.118 0.352 0.384 0.056 0.075
8178811 HLA-DRB1 0.973 <10−4 0.047 0.246 0.257 0.483 0.504 0.129 0.141
8180003 HLA-DRB1 0.944 <10−4 0.043
7965403 LUM 1.274 <10−4 0.043 0.113 0.132 0.003 0.008 0.005 0.015
8129573 MOXD1 0.607 <10−4 0.016 0.009 0.024 0.013 0.024 0.371 0.387
7908924 PRELP 0.788 <10−4 0.046 0.076 0.117 0.023 0.036 0.032 0.050
7977615 RNASE1 0.714 <10−4 0.042 0.283 0.283 0.278 0.318 0.126 0.141
8103254 SFRP2 0.727 <10−4 0.008 0.001 0.003 <10−4 0.001 0.009 0.022
8139087 SFRP4 1.074 <10−4 0.002 <10−4 0.001 <10−4 <10−4 0.001 0.007
8146863 SULF1 0.721 <10−4 0.012 0.011 0.024 <10−4 <10−4 0.001 0.007
8130867 THBS2 0.678 <10−4 0.012 <10−4 0.001 0.005 0.010 0.001 0.007
7952268 THY1 0.589 <10−4 0.043 0.006 0.019 0.015 0.025 0.012 0.024
8101774 TMSB4X 0.657 <10−4 0.042 NA NA 0.728 0.728 0.817 0.817
8067007 TMSB4X 0.664 <10−4 0.043
8166072 TMSB4X 0.675 <10−4 0.049
FDR false discovery rate, LCM laser capture microdissection
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responsive process in prostate cells and an aberrant UPR can lead
to suppression of apoptosis, increased protein expression, and
survival of prostate cancer cells. Metabolic challenges such as
ﬂuctuations in nutrient availability, hypoxia and increased
demand on protein synthesis, can lead to perturbation of
endoplasmic reticulum (ER) function, accumulation of misfolded
proteins, and ER stress. In an attempt to restore ER homeostasis,
the cell mounts a response called the UPR, a set of intracellular
signaling pathways that aim to adjust the protein folding
capacity of the cell38. Translational control of protein synthesis is
therefore important for prostate cancer cell proliferation and
survival but the role of stromal cells in this regard is novel,
perhaps suggesting that a stromal environment exists in some
individuals that is permissive for survival and proliferation of
transformed epithelial cells.
Gleason grade is one of the strongest clinical predictors of
prostate cancer progression and outcomes. An mRNA signature
associated with Gleason grade improves risk stratiﬁcation23.
We identiﬁed only one gene differentially expressed between
high-grade and low-grade tumor epithelium, ALCAM, a TGFβ
responsive gene, previously shown to be associated with
metastasis35. It is well known that TGF beta signaling plays
important regulatory roles in stromal-epithelial interactions in
both prostate development and tumorigenesis. Differences
between gene expression in stroma adjacent to high-grade
and low-grade cancer were much more striking: 25 genes
were differentially expressed. All genes comprising this stromal
signature of Gleason were more highly expressed in stroma from
high-Gleason cases than those from low grade. The fact that gene
expression from stroma across Gleason grades is more different
than that in the epithelial tumor compartment conﬁrms the
importance of the microenvironment and suggests that more
work to develop drugs that speciﬁcally target the stroma is
warranted.
Interestingly, among the 24 stromal genes differentially
expressed across high and low grade were genes expressed by the
immune system including complement, as well as many
genes that are expressed in osteoblasts and osteoblast-like cells.
The complement cascade is known to be an effector arm of innate
immunity, playing a role in clearance of pathogens as well as in
tumor immune surveillance. The complement system also plays a
role in cartilage and bone development, as well as in regenerative
pathways in injured tissue (reviewed in ref. 39). Of note, some
complement proteins are distributed throughout immature,
developing bone and appear to be important in osteogenesis.
Uncontrolled complement activation can also promote
inﬂammation. Consistent with these ﬁndings, bone remodeling
pathways were upregulated predominantly in stroma adjacent to
malignant epithelium, and to a much lesser extent in benign or
PIN adjacent stroma. The stromal genes lumican (LUM),
COL1A1 and BGN, belonging to both the signature we report
here and comprising all stromal genes in the commercial Onco-
typeDx kit40, are also interesting in terms of the theme of bone
remodeling. COL1A1 is an osteoblastic differentiation marker41
and BGN modulates angiogenesis and bone formation during
fracture healing42. As prostate cancer most commonly
metastasizes to bone, and Gleason 8 tumors are more likely to
metastasize than Gleason 6, the ﬁnding of the overexpression of
bone remodeling pathway in high-grade stroma is particularly
interesting. The interaction of prostate cancer with the bone
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microenvironment contributes to self-perpetuating progression of
cancer in bone and the osteoclast-targeted agents zoledronic acid
and denosumab decrease metastases to bone in metastatic
castration-resistant prostate cancer43. We speculate that this
prostate stromal environment may prepare cells from high-grade
tumors to thrive in bone.
We successfully validated the association of the stromal
Gleason signature with Gleason score in TCGA data. Not
surprisingly, the signature was more strongly associated
with Gleason in tumors with lower purity that have a higher
percentage of stromal tissue. The signature was also signiﬁcantly
associated with lethal disease in expression data from the
Mayo clinic cohort, although its prognostic power is likely to be
suboptimal in this patient data set because the Mayo clinic
data was designed to be enriched for epithelium. As the analysis
of TCGA data suggests, we expect to observe stronger perfor-
mance of the signature for prostate cancer prognosis in the
stroma enriched specimens. A recently published study44 that
utilized patient derived xenograft models to develop a stromal
signature of metastatic potential corroborates our ﬁndings that
gene expression in stroma is predictive of prostate cancer
outcome.
Interestingly, this Gleason signature was also borderline
signiﬁcantly different in stroma from benign areas of the
prostates with high-grade and low-grade tumors. Additionally,
when examining all gene expression data, we observed that
benign stroma from men with high-grade tumors was more
similar to cystoprostatectomy stroma than low-grade benign
stroma, despite the fact that in our samples benign stroma from
high-grade cases was physically closer to a tumor focus than in
low-grade cases. This could suggest that there is a “prostate-wide”
difference in the stroma of men who develop low-grade disease
that allows for the development of well differentiated cancer with
low malignant potential. Additional larger scale studies with
benign stroma from healthy individuals and prostate cancer
patients’ samples taken repeatedly at different distances from
tumor foci are needed to validate these ﬁndings. However, if
conﬁrmed, this would provide convincing evidence that it might
be possible to identify a prognostic signature from stroma
from biopsies that do not contain malignant epithelial cells. In
prostate cancer, negative biopsies are a common occurrence and a
signiﬁcant clinical problem that results from random sampling in
a PSA screened population. After a man has had an elevated PSA,
but a negative biopsy, the normal stroma could be used to
determine if he seems at risk only for low-grade disease or at
risk for aggressive disease. This could help determine if and
when he should return for a follow-up biopsy. In addition, a
stromal signature in biopsies without neoplastic tissue may be of
importance in the context of active surveillance.
While, we focused on comparing patients with Gleason scores
6 and 8+, many men are diagnosed with Gleason score 7 disease.
The data from our current study does not permit us to comment
on how the stroma behaves in these patients, but from the Mayo
cohort data and TCGA data, it appears that the stromal signature
in Gleason score 7 tumors falls in between Gleason score 6 and 8,
suggesting an intermediate state of Gleason 7 stroma. A
further investigation of the stroma in Gleason score 7 cases
is necessary to clarify the gene expression proﬁles of stroma
adjacent to pattern 3 and pattern 4 within Gleason 7.
This study comprehensively assesses gene expression from
microdissected prostate tissue specimens, focusing on epithelial
and stromal compartments across progression. Despite the
moderate sample size used for discovery and scarcity of the
external gene expression data from specimens with high stromal
content, we were able to validate our key ﬁndings in the publicly
available data.
Methods
Clinical specimens. A total of 135 prostate cancer patients who underwent
radical prostatectomy have been recruited from the following Institutions: Harvard
School of Public Health, Boston, USA; Guy’s and St Thomas NHS Foundation
Trust/King’s College London, UK; Prostate Cancer Research Consortium, Ireland;
Orebro University Hospital, Sweden; S.Orsola-Malpighi Hospital Bologna, Italy. All
patients provided informed written consent approved by each local IRB and
research ethics committees.
Pathologists selected prostate cancer cases with Gleason grade 6 and Gleason
grade ≥8. Cases with Gleason 7 were excluded from the study. Cases were selected
according to the presence of sufﬁcient amount of PIN, prostate cancer and normal
prostate tissue in the same block/slide. In addition, cases with minimal
inﬂammation were chosen. Immunohistochemistry for CD45 and CD163 were
performed to assess the lymphocytic and macrophage inﬁltrate, respectively
(Supplementary Fig. 4). After case review 25 cases were ﬁnally selected for the
study. Thirty prostates from cystoprostatectomy cases were collected from patients
with bladder cancer to be included in the study as normal controls for prostate.
Cystoprostatectomy patients were not treated with BCG. Among the
cystoprostatectomies the cases with incidental prostate cancer or excessive
inﬂammation in the stromal component or atrophy in the epithelial component
were excluded after pathology review and 5 out of 30 cases were selected for
microdissection.
Digital-pathology. Slide digitalization and circling of the regions of interest
(ROI) was centralized. The slides selected according to the above criteria were
scanned with an Aperio CS2 instrument and put on a dedicated proprietary
website protected by regulated access. Separate circling of the epithelial and
stromal components in cancer, PIN and normal tissue areas was performed
on digitalized H&Es using the Aperio ImageScope software V.10.35.1800
(representative examples of circling are shown in Supplementary Fig. 5). Annotated
pathology scans were remotely accessed for the laser capture microdissection.
Laser capture microdissection and gene expression proﬁling. Following ROI
review by digital annotation, LCM was performed on the Arcturus platform
(Life Technologies), overnight incubation in lysis buffer/Proteinase K and
subsequent RNA extraction by AllPrep (Qiagen) and quantiﬁcation by RiboGreen
assay (Life Technology). The differences between the means of stromal areas
captured by LCM between Gleason 6 and Gleason 8 cases were not statistically
signiﬁcant (two-sample t-test P-values were 0.41, 0.2, and 0.88 for sB, sP and sT
areas, respectively). The images of all LCM caps with captured ROI areas are
available upon request. To accommodate the low RNA concentration and yields
associated with microdissected tissues, we utilized the SensationPlus FFPE method.
Twenty nanograms of total RNA at a concentration of 2.5 ng/μl was used to
measure RNA expression across the whole transcriptome on the Affymetrix Gene
Array STA 1.0.
Normalization and differential gene expression analysis. Pre-processing of the
microarray data consisted of adjusting raw data at the probe level for technical
variables, such as batches, overall median of the ﬂuorescence intensities in each
array and fraction of the probes with intensity higher than background levels.
Adjusted values were normalized using RMA (robust multichip average) method45.
There were no extreme outliers or failing samples, therefore we retained all assayed
samples and ROIs for further analysis. We used transcript clusters from the ‘main’
category with log-median intensity of three in at least one of the ROIs.
We used random effects linear models approach to account for correlations
between compartments within cases using Bioconductor package limma46. We
adjusted for multiple comparisons using the Benjamini-Hochberg false discovery
rate (FDR) method. A FDR ≤0.05 was considered signiﬁcant. Signiﬁcantly
differentially expressed genes with the fold-changes not exceeding 1.5 were not
reported. For pathway analysis we used a Wilcoxon test implemented in
geneSetTest function in limma, signed and unsigned moderated t-statistics from
linear model ﬁts were used to rank the genes. Overrepresentation analysis for
Supplementary Data 2 was done using Fisher’s exact test. Gene Ontology
Biological Processes annotations were downloaded from MSigDb47 (used for all
analysis) and Enrichment Map Gene Sets collections (http://download.baderlab.
org/EM_Genesets/, used for the analysis presented in Fig. 3d and Supplementary
Data 2). For analysis we only considered gene sets with less than 200 and more
than 20 genes. Benjamini-Hocheberg FDR method was used to correct for multiple
comparisons.
To identify GO biological processes enriched in the epithelial (or stromal)
compartment across progression for Fig. 1 we identiﬁed genes overexpressed in
epithelium and in stroma in benign tissue from cystoprostatectomies (H), in
benign tissue from RP (B), PIN form RP (P), and tumor from RP (T). Direction
and strength of overexpression was identiﬁed from the sign and magnitude of the
moderated t-statistic in the corresponding linear model contrasts: H.B-H.sB, B-sB,
P-sP and T-sT. For subsequent for gene sets The genes were ranked accordingly to
their overexpression in epithelial and stromal compartments for subsequent gene
sets analysis.
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ssGSEA signature score. ssGSEA scores were computed using GSVA
Bioconductor package. The ssGSEA algorithm assigns an enrichment score for
each sample, that characterizes joint up- or down- regulation of a set of genes
(in our case the set of genes comprising a stromal signature) in relation to
remaining reference genes measured in the sample. We used the genes that
were signiﬁcantly upregulated in sT vs T comparison as a reference set (logFC
thresholding was not applied here) for computing the score. We used the ssGSEA
signature score to compare joint overexpression of the genes that belong to the
signature between different samples in the LCM gene expression data and in the
publicly available data used for validation. Higher ssGSEA scores correspond to
stronger joint upregulation of the signature genes. For the TCGA and GSE46697
data sets both signature genes and reference set were subsetted to the genes
measured in each study.
Selection of stromally enriched samples. In order to identify stromally
enriched GSE46691 samples, we computed ssGSEA scores of the genes found to be
signiﬁcantly different with negative logFC in T-sT comparison (~ 3000 genes) in
our LCM data using all measured genes as reference set. The scores computed on
this set of genes had high correlations 0.34 and 0.82 with 1-Tumor Cellularity
values inferred by pathologist and RNA-Seq-based computational estimates in
TCGA data. Stromally enriched samples were deﬁned as those having score above
the median of the distribution of the score across all samples.
Immunohistochemistry. Immunohistochemical staining of ALCAM and SULF1
was performed on 4 µm sections using the Bond Reﬁne Detection System on the
Leica Bond Rx automated immunostainer. The sections were automatically
deparafﬁnized, antigen retrieval was done with Citrate buffer (pH 6.0) and
processed for 20 min. The slides were incubated with the antibody against ALCAM
(Rb polyclonal, HPA010926, Sigma-Aldrich) and SULF1 (Rabbit polyclonal,
HPA054728, Sigma-Aldrich) at dilution of 1:200 for 60 min, respectively.
Normal stomach tissue was used as positive controls for ALCAM, and smooth
muscle tissue was used as positive controls for SULF1, respectively. Smooth muscle
and liver were used for negative/weak control for ALCAM and SULF1, respectively.
Omission of the primary antibody was utilized as a blank control.
For double immunohistochemistry staining, 4 µm FFPE sections were prepared,
after deparafﬁnization, and antigen retrieval sections were incubated with primary
antibodies, anti-CD45 (Rb monoclonal, #13917, Cell Signal Technology) at dilution
of 1:250 and CD163 (Ms mAb, NCL-L-CD163, Leica Biosystems) at dilution of
1:200 for 30 min. Followed with MACH2 Double stain 2 antibodies (Mouse-HRP
+ Rabbit-AP, MRCT525, Biocare) for 30 min at room temperature. With Vulcan
Fast Red (FR805, Biocare) and Betazoid DAB (BDB2004, Biocare) as Chromogens,
CD45 signal is red and CD163 signals as brown, and then counterstained with
hematoxylin. Tonsil was used as positive controls for CD45, placenta was used
as positive controls for CD163; and colon and skeletal muscle were used for
negative/weak controls.
Data availability. LCM gene expression data generated and analyzed in this study
was deposited to the Gene Expression Omnibus (GEO) with accession number
GSE97284. Annotations for 333 TCGA prostate cancer samples were downloaded
from cBioPortal (http://www.cbioportal.org/study?id=prad_tcga_pub#summary)
and corresponding RSEM normalized gene expression values from FireHose portal
(http://ﬁrebrowse.org/?cohort=PRAD&download_dialog=true). Mayo clinic
cohort data were downloaded from GEO, accession number GSE46691. All other
remaining data are available within the Article and Supplementary Files, or
available from the authors upon request.
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